Your session is about to expire
← Back to Search
This trial will test whether stereotactic radiosurgery/SRS is an effective treatment for people newly diagnosed with brain metastases from small cell lung cancer/SCLC.
- Lung Cancer
- Brain Metastases
- Brain Tumor
- Small Cell Lung Cancer
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2019 Phase 2 trial • 32 Patients • NCT01573702
Awards & Highlights
Find a Location
Who is running the clinical trial?
- You are able to perform daily activities and are in good physical condition.You have been diagnosed with small cell lung cancer.You must be 18 years old or older.You are unable to have a special type of MRI with a contrast dye for your brain or spine.You have been diagnosed with leptomeningeal disease confirmed through specific medical tests.You have had radiation treatment specifically to your brain in the past.You have a serious disease that is not being well managed with treatment options and may lead to death within 3 months.You have been diagnosed with small cell lung cancer.You have been diagnosed with up to 10 brain tumors using a special type of MRI scan.You are able to perform daily activities with little to no difficulty.You have been diagnosed with up to 10 brain metastases through a special type of MRI scan.If you are a female, you cannot be pregnant or have the potential to become pregnant.
- Group 1: Participants with small cell lung cancer with brain metastases
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there an active recruitment process for this trial?
"This clinical trial, which was initially advertised on June 10th 2022 according to clinicialtrials.gov is actively recruiting participants. The post has been amended most recently on November 11th 2022."
Has Stereotactic Radiosurgery been accepted and certified by the Food and Drug Administration?
"Preliminary evidence suggests that Stereotactic Radiosurgery is safe, granting it a rating of 2. Nevertheless, this Phase 2 trial has yet to provide data supporting the efficacy of such treatments."
What is the size of the sample population for this experiment?
"Affirmative. According to clinicaltrials.gov, this medical study is still in search of suitable candidates after being initially posted on June 10th 2022 and last edited November 11th 2022. At present, it requires 62 patients across 7 sites."
How many sites are responsible for administering this experiment?
"Currently, seven medical centres are actively recruiting patients. A few of these include Memorial Sloan Kettering Suffolk - Commack in Commack, Memorial Sloan Kettering Cancer Center (All Protocol Activities) in New Yorkg Cancer Center (All Protocol Activities) in New York, and the Memorial Sloan Kettering Bergen site in Montvale."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How responsive is this trial?
Most responsive sites:
- Memorial Sloan Kettering Bergen: < 24 hours
Typically responds via
Average response time
- < 1 Day
Share this study with friends